Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H.P. Acthar for Intraocular Inflammation in PVR
NCT03727776Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Aug 2019
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of repository corticotropin injection in Proliferative Vitreoretinopathy (PVR) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Aqueous levels of albumin at 8 weeks, Aqueous levels of Transforming Growth Factor-Beta at 8 weeks and 1 more. Started Aug 2019; status: completed.
02
Drugs
repository corticotropin injection
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT03727776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727776.